Samantha E Halpern1, Sandra Au2, Samuel J Kesseli3, Madison K Krischak2, Danae G Olaso2, Brandi A Bottiger4, John C Haney3, Jacob A Klapper3, Matthew G Hartwig3. 1. School of Medicine, Duke University, Durham, North Carolina. Electronic address: samantha.halpern@duke.edu. 2. School of Medicine, Duke University, Durham, North Carolina. 3. Division of Cardiovascular and Thoracic Surgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina. 4. Department of Anesthesiology, Duke University Medical Center, Durham, North Carolina.
Abstract
BACKGROUND: Six hours was historically regarded as the limit of acceptable ischemic time for lung allografts. However, broader sharing of donor lungs often necessitates use of allografts with ischemic time >6 hours. We characterized the association between ischemic time ≥8 hours and outcomes after lung transplantation using a contemporary cohort from a high-volume institution. METHODS: Patients who underwent primary isolated bilateral lung transplantation between 1/2016 and 5/2020 were included. Patients bridged to transplant with extracorporeal membrane oxygenation or mechanical ventilation, and ex-vivo perfusion cases were excluded. Recipients were stratified by total allograft ischemic time <8 hours (standard) vs ≥8 hours (long). Perioperative outcomes and post-transplant survival were compared between groups. RESULTS: Of 358 patients, 95 (26.5%) received long ischemic time (≥8 hours) lungs. Long ischemic time recipients were more likely to be male and have donation after circulatory death donors than standard ischemic time recipients. On unadjusted analysis, long and standard ischemic time recipients had similar survival, and similar rates of grade 3 primary graft dysfunction at 72 hours, extracorporeal membrane oxygenation post-transplant, acute rejection within 30 days, reintubation, and post-transplant length of stay. After adjustment, long and standard ischemic time recipients had comparable risks of mortality or graft failure. CONCLUSIONS: In a modern cohort, use of lung allografts with "long" ischemic time ≥8 hours were associated with acceptable perioperative outcomes and post-transplant survival. Further investigation is required to better understand how broader use impacts post-lung transplant outcomes and the implications for smarter sharing under an evolving national allocation policy.
BACKGROUND: Six hours was historically regarded as the limit of acceptable ischemic time for lung allografts. However, broader sharing of donor lungs often necessitates use of allografts with ischemic time >6 hours. We characterized the association between ischemic time ≥8 hours and outcomes after lung transplantation using a contemporary cohort from a high-volume institution. METHODS: Patients who underwent primary isolated bilateral lung transplantation between 1/2016 and 5/2020 were included. Patients bridged to transplant with extracorporeal membrane oxygenation or mechanical ventilation, and ex-vivo perfusion cases were excluded. Recipients were stratified by total allograft ischemic time <8 hours (standard) vs ≥8 hours (long). Perioperative outcomes and post-transplant survival were compared between groups. RESULTS: Of 358 patients, 95 (26.5%) received long ischemic time (≥8 hours) lungs. Long ischemic time recipients were more likely to be male and have donation after circulatory death donors than standard ischemic time recipients. On unadjusted analysis, long and standard ischemic time recipients had similar survival, and similar rates of grade 3 primary graft dysfunction at 72 hours, extracorporeal membrane oxygenation post-transplant, acute rejection within 30 days, reintubation, and post-transplant length of stay. After adjustment, long and standard ischemic time recipients had comparable risks of mortality or graft failure. CONCLUSIONS: In a modern cohort, use of lung allografts with "long" ischemic time ≥8 hours were associated with acceptable perioperative outcomes and post-transplant survival. Further investigation is required to better understand how broader use impacts post-lung transplant outcomes and the implications for smarter sharing under an evolving national allocation policy.
Authors: Joshua M Diamond; Selim Arcasoy; Cassie C Kennedy; Michael Eberlein; Jonathan P Singer; Glenda M Patterson; Jeffrey D Edelman; Gundeep Dhillon; Tahuanty Pena; Steven M Kawut; James C Lee; Reda Girgis; John Dark; Gabriel Thabut Journal: J Heart Lung Transplant Date: 2017-07-26 Impact factor: 10.247
Authors: Jonathan C Yeung; Thorsten Krueger; Kazuhiro Yasufuku; Marc de Perrot; Andrew F Pierre; Thomas K Waddell; Lianne G Singer; Shaf Keshavjee; Marcelo Cypel Journal: Lancet Respir Med Date: 2016-11-18 Impact factor: 30.700
Authors: J S Gammie; D R Stukus; S M Pham; B G Hattler; M F McGrath; K R McCurry; B P Griffith; R J Keenan Journal: Ann Thorac Surg Date: 1999-12 Impact factor: 4.330
Authors: S M Fiser; I L Kron; S M Long; A K Kaza; J A Kern; D C Cassada; D R Jones; M C Robbins; C G Tribble Journal: J Heart Lung Transplant Date: 2001-12 Impact factor: 10.247
Authors: Gabriel Thabut; Hervé Mal; Jacques Cerrina; Philippe Dartevelle; Claire Dromer; Jean-François Velly; Marc Stern; Philippe Loirat; Guy Lesèche; Michelle Bertocchi; Jean-François Mornex; Alain Haloun; Philippe Despins; Christophe Pison; Dominique Blin; Martine Reynaud-Gaubert Journal: Am J Respir Crit Care Med Date: 2005-01-21 Impact factor: 21.405
Authors: Varun Puri; Ramsey R Hachem; Christian Corbin Frye; Margaret Shea Harrison; Tara R Semenkovich; John P Lynch; Gene Ridolfi; Casey Rowe; Bryan F Meyers; George Alexander Patterson; Benjamin D Kozower; Michael K Pasque; Ruben G Nava; Gary F Marklin; Diane Brockmeier; Stuart C Sweet; William C Chapman; Daniel Kreisel Journal: Am J Transplant Date: 2019-03-18 Impact factor: 8.086
Authors: Catherine L Kuntz; Denis Hadjiliadis; Vivek N Ahya; Robert M Kotloff; Alberto Pochettino; James Lewis; Jason D Christie Journal: Clin Transplant Date: 2009-02-20 Impact factor: 2.863